Ontogeny, Brigham and Women's Hospital, Dana-Farber Cancer Institute, University of California deal

Ontogeny will evaluate compounds to treat basal cell carcinoma (BCC) using UCSF's animal model of the skin cancer.

Separately, Ontogeny will research BCC and identify additional compounds to treat the disease in collaboration with Brigham and Women's and Dana-Farber researchers. The academic institutions will provide expertise in cell culture, transgenic animals and human BCC cells, and Ontogeny will use the cells to study the role of the patched protein in development of BCC and evaluate compounds...